Sources in thyroid cancer studies for medical and non-medical costs of economic evaluation
| Type of costs | Total N (%) | CA+CMA |
CEA+CUA |
|---|---|---|---|
| Medical direct costs | |||
| Medicare reimbursement | 15 (30.6) | 5 (10.2) | 10 (20.4) |
| Medicare reimbursement+Raw data |
10 (20.4) | 3 (6.1) | 7 (14.3) |
| Raw data | 9 (18.4) | 4 (8.2) | 5 (10.2) |
| Medicare reimbursement+SR |
8 (16.3) | 1 (2.0) | 7 (14.3) |
| SR | 4 (8.2) | 4 (8.2) | |
| SR+Medicare reimbursement+Raw data | 2 (4.1) | 2 (4.1) | |
| SR+Raw data | 1 (2.0) | 1 (2.0) | |
| Total | 49 (100.0) | 13 (26.5) | 36 (73.5) |
| Non-medical direct costs | |||
| Traffic charge | 1 (2.0) | 1 (2.0) | |
| Not included | 48 (98.0) | 13 (26.5) | 35 (71.4) |
| Total | 49 (100.0) | 13 (26.5) | 36 (73.5) |
| Indirect costs | |||
| Productivity loss |
12 (24.5) | 12 (24.5) | |
| Expenses related to death | 3 (6.1) | 1 (2.0) | 2 (4.1) |
| Productivity loss+Expenses related to death | 1 (2.0) | 1 (2.0) | |
| Not included | 33 (67.3) | 12 (24.5) | 21 (42.9) |
| Total | 49 (100.0) | 13 (26.5) | 36 (73.5) |
CA: cost analysis, CEA: cost-effectiveness analysis, CMA: cost-minimization analysis, CUA: cost-utility analysis, N: number, SR: systematic review
aCA and CMA studies are presented in a single column, since both evaluation methods compare the costs of the intervention.
bCEA and CUA studies are presented in a single column, since both evaluation methods compare the effectiveness of the intervention.
cClinical trial, registry, or single hospital data.
dSR for medical direct costs.
eLoss of work/revenue/production caused by the unavailability of an employee for any reason.